(0.19%) 5 141.25 points
(0.19%) 38 515 points
(0.26%) 17 893 points
(-0.73%) $83.24
(1.87%) $1.959
(0.03%) $2 348.00
(0.03%) $27.54
(0.70%) $928.60
(-0.14%) $0.933
(-0.20%) $11.00
(-0.24%) $0.798
(1.07%) $92.86
Live Chart Being Loaded With Signals
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis...
Stats | |
---|---|
今日成交量 | 1 419.00 |
平均成交量 | 6 052.00 |
市值 | 173.41M |
EPS | $0 ( 2024-04-11 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.63 |
ATR14 | $0 (0.00%) |
Genfit SA 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Genfit SA 财务报表
Annual | 2023 |
营收: | $28.57M |
毛利润: | $28.22M (98.81 %) |
EPS: | $-0.580 |
FY | 2023 |
营收: | $28.57M |
毛利润: | $28.22M (98.81 %) |
EPS: | $-0.580 |
FY | 2022 |
营收: | $20.20M |
毛利润: | $19.95M (98.77 %) |
EPS: | $-0.480 |
FY | 2021 |
营收: | $80.07M |
毛利润: | $0.00 (0.00 %) |
EPS: | $1.510 |
Financial Reports:
No articles found.
Genfit SA
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。